Cytosorbents Co. (CTSO) CFO Kathleen P. Bloch Sells 10,000 Shares

Cytosorbents Co. (NASDAQ:CTSO) CFO Kathleen P. Bloch sold 10,000 shares of the business’s stock in a transaction on Wednesday, February 21st. The shares were sold at an average price of $8.00, for a total transaction of $80,000.00. Following the sale, the chief financial officer now directly owns 268,870 shares in the company, valued at $2,150,960. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Shares of NASDAQ CTSO traded up $0.02 during mid-day trading on Friday, reaching $7.42. The company had a trading volume of 17,209 shares, compared to its average volume of 184,911. Cytosorbents Co. has a twelve month low of $3.30 and a twelve month high of $8.25. The company has a current ratio of 2.64, a quick ratio of 2.54 and a debt-to-equity ratio of 0.58. The company has a market capitalization of $215.14, a PE ratio of -23.13 and a beta of -0.09.

How to Become a New Pot Stock Millionaire

Cytosorbents (NASDAQ:CTSO) last posted its quarterly earnings results on Thursday, March 8th. The medical research company reported ($0.12) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.10) by ($0.02). The company had revenue of $4.65 million during the quarter, compared to analyst estimates of $4.56 million. Cytosorbents had a negative return on equity of 118.07% and a negative net margin of 52.08%. analysts predict that Cytosorbents Co. will post -0.47 EPS for the current year.

A number of equities analysts have recently weighed in on the stock. Maxim Group set a $12.00 price target on shares of Cytosorbents and gave the stock a “buy” rating in a research note on Monday, January 8th. ValuEngine downgraded shares of Cytosorbents from a “hold” rating to a “sell” rating in a research note on Friday, December 15th. B. Riley reaffirmed a “buy” rating and issued a $11.25 price target on shares of Cytosorbents in a research note on Thursday, January 25th. HC Wainwright reaffirmed a “buy” rating and issued a $14.00 price target on shares of Cytosorbents in a research note on Tuesday, January 9th. Finally, Cowen set a $9.00 price target on shares of Cytosorbents and gave the stock a “buy” rating in a research note on Thursday, March 8th. Six analysts have rated the stock with a buy rating, Cytosorbents currently has an average rating of “Buy” and a consensus target price of $11.05.

A number of large investors have recently modified their holdings of the stock. PEAK6 Investments L.P. boosted its holdings in Cytosorbents by 13.7% in the fourth quarter. PEAK6 Investments L.P. now owns 99,744 shares of the medical research company’s stock worth $648,000 after purchasing an additional 12,022 shares in the last quarter. Millennium Management LLC boosted its holdings in Cytosorbents by 297.8% in the fourth quarter. Millennium Management LLC now owns 163,977 shares of the medical research company’s stock worth $1,066,000 after purchasing an additional 122,760 shares in the last quarter. Raymond James & Associates boosted its holdings in Cytosorbents by 100.0% in the fourth quarter. Raymond James & Associates now owns 100,000 shares of the medical research company’s stock worth $650,000 after purchasing an additional 50,000 shares in the last quarter. Goldman Sachs Group Inc. bought a new stake in Cytosorbents in the fourth quarter worth $146,000. Finally, BlueCrest Capital Management Ltd bought a new stake in Cytosorbents in the fourth quarter worth $396,000. Hedge funds and other institutional investors own 10.84% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Cytosorbents Co. (CTSO) CFO Kathleen P. Bloch Sells 10,000 Shares” was first reported by Ticker Report and is the property of of Ticker Report. If you are reading this piece on another website, it was stolen and reposted in violation of U.S. & international copyright and trademark law. The correct version of this piece can be read at https://www.tickerreport.com/banking-finance/3335264/cytosorbents-co-ctso-cfo-kathleen-p-bloch-sells-10000-shares.html.

Cytosorbents Company Profile

CytoSorbents Corporation, a critical care focused immunotherapy company, engages in the research, development, and commercialization of medical devices with its platform blood purification technology incorporating a proprietary adsorbent, porous polymer technology. Its principal product is CytoSorb device, an extracorporeal cytokine filter designed for the adjunctive therapy in the treatment of sepsis; adjunctive therapy in other critical care applications; prevention and treatment of post-operative complications of cardiopulmonary bypass surgery; and prevention and treatment of organ dysfunction in brain-dead organ donors to increase the number and quality of viable organs harvested from donors.

Insider Buying and Selling by Quarter for Cytosorbents (NASDAQ:CTSO)

Receive News & Ratings for Cytosorbents Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

PS Business Parks  Scheduled to Post Quarterly Earnings on Monday
PS Business Parks Scheduled to Post Quarterly Earnings on Monday
American National Ins  Scheduled to Post Earnings on Monday
American National Ins Scheduled to Post Earnings on Monday
Arch Capital Group  Set to Announce Quarterly Earnings on Monday
Arch Capital Group Set to Announce Quarterly Earnings on Monday
New Age Beverages  Stock Price Down 9.4% on Analyst Downgrade
New Age Beverages Stock Price Down 9.4% on Analyst Downgrade
Scotiabank Reiterates C$4.75 Price Target for Premier Gold Mines
Scotiabank Reiterates C$4.75 Price Target for Premier Gold Mines
BMO Capital Markets Increases Roots  Price Target to C$16.00
BMO Capital Markets Increases Roots Price Target to C$16.00


© 2006-2018 Ticker Report. Google+.